The 'right to repair' debate is one that could impact heart teams and device manufacturers for years to come. Some hospitals have had a head start, accusing one company of unfair repair policies that put patients at risk.
The medication is approved for slowing CKD progression in patients with type 2 diabetes. It can also reduce a patient's risk of heart failure hospitalization and cardiovascular death.
Researchers in Japan are focused on uncovering new data on the body's response to a high-fat diet, hoping their work can lead to improved treatment options in the future.